NASDAQ:SCNX Scienture (SCNX) Stock Price, News & Analysis $2.14 +0.05 (+2.39%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Scienture Stock (NASDAQ:SCNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Scienture alerts:Sign Up Key Stats Today's Range$2.10▼$2.3750-Day Range$0.90▼$2.3952-Week Range$0.69▼$10.23Volume184,702 shsAverage Volume1.24 million shsMarket Capitalization$34.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. Read More Receive SCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scienture and its competitors with MarketBeat's FREE daily newsletter. Email Address SCNX Stock News HeadlinesScienture announces shipment of launch quantities of Arbli Oral Suspension1 hour ago | msn.comScienture Holdings, Inc. to Launch Arbli™ Oral Suspension for Hypertension Treatment in the U.S. marketAugust 13 at 8:38 AM | quiverquant.comQMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 13 at 2:00 AM | Brownstone Research (Ad)SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.August 13 at 8:05 AM | globenewswire.comScienture (NASDAQ:SCNX) Upgraded to "Hold" at Wall Street ZenAugust 11 at 2:51 AM | americanbankingnews.comScienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding | SCNX Stock NewsJuly 24, 2025 | gurufocus.comScienture Holdings Secures $1.2 Million in Capital RaiseJuly 24, 2025 | tipranks.comScienture Holdings, Inc. Secures $3 Million Bridge Funding to Support Product Launches and Pipeline DevelopmentJuly 24, 2025 | quiverquant.comQSee More Headlines SCNX Stock Analysis - Frequently Asked Questions How have SCNX shares performed this year? Scienture's stock was trading at $6.05 on January 1st, 2025. Since then, SCNX stock has decreased by 64.6% and is now trading at $2.14. How were Scienture's earnings last quarter? Scienture Holdings, Inc. (NASDAQ:SCNX) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter. Scienture had a negative trailing twelve-month return on equity of 22.57% and a negative net margin of 10,364.22%. How do I buy shares of Scienture? Shares of SCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scienture own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scienture investors own include Cogent Communications (CCOI), Cavco Industries (CVCO), Liberty Broadband (LBRDK), Liberty Global (LBTYB), PayPal (PYPL), Roku (ROKU) and Arch Capital Group (ACGL). Company Calendar Last Earnings8/12/2025Today8/13/2025Next Earnings (Estimated)8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryWholesale Current SymbolNASDAQ:SCNX CIK1382574 Webwww.trxadehealth.com Phone(800) 261-0281Fax800-265-6932EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$9.07 million Net Margins-10,364.22% Pretax Margin-10,341.10% Return on Equity-22.57% Return on Assets-18.12% Debt Debt-to-Equity Ratio0.01 Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$140 thousand Price / Sales240.80 Cash FlowN/A Price / Cash FlowN/A Book Value$9.04 per share Price / Book0.23Miscellaneous Outstanding Shares16,130,000Free Float8,114,000Market Cap$33.71 million OptionableN/A Beta2.94 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SCNX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scienture Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scienture With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.